PetDx

PetDx is a startup that operates in the pet healthcare market, specifically focusing on early cancer detection in dogs. The company has developed a product called OncoK9, a multi-cancer early detection (MCED) test that uses a simple blood draw. This test is based on liquid biopsy technology, which is a non-invasive method that detects cancer by analyzing fragments of DNA released into the bloodstream by cancer cells.

The company's primary clients are veterinarians in North America, who can order the test directly from PetDx or through its partners. The test is designed to detect cancer in its early stages, when treatment options are more effective and chances of long-term control or cure are higher. This is particularly important considering that cancer is the most common cause of death in adult dogs, with approximately 6 million new cases diagnosed each year in the United States alone.

PetDx's business model revolves around the sale of the OncoK9 test. The company generates revenue from each test sold to veterinarians. The value proposition of PetDx lies in its potential to extend the lives of dogs by enabling early detection and treatment of cancer, which could otherwise go undetected until its advanced stages.

Keywords: PetDx, OncoK9, early cancer detection, dogs, liquid biopsy technology, genomic analysis, next-generation sequencing, veterinarians, pet healthcare, non-invasive testing.